08:02 AM EDT, 09/18/2026 (MT Newswires) -- A committee under the European Medicines Agency recommended granting marketing authorization for Gevalka as a treatment for adults with anaplastic lymphoma kinase, or ALK-positive, advanced non-small cell lung cancer, or NSCLC. Gevalka, submitted for approval by SFL Pharmaceuticals Deutschland, contains the active substance ensartinib and will be available in 25-milligram and 100-mg capsules, according to a Friday release. In a study of adults with locally advanced or metastatic ALK-positive NSCLC, the drug demonstrated an improvement in progression-free survival in the first-line setting. Following the Committee for Medicinal Products for Human Use's positive opinion, the European Commission will now make its decision on the treatment based on the recommendation.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.